NASDAQ:SRNE

Sorrento Therapeutics Competitors

$7.56
+0.14 (+1.89 %)
(As of 04/21/2021 01:17 PM ET)
Add
Compare
Today's Range
$7.35
Now: $7.56
$7.76
50-Day Range
$6.93
MA: $8.64
$10.40
52-Week Range
$2.18
Now: $7.56
$19.39
Volume139,498 shs
Average Volume15.45 million shs
Market Capitalization$2.16 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.7

Competitors

Sorrento Therapeutics (NASDAQ:SRNE) Vs. FATE, XLRN, HALO, DNLI, VIR, and TWST

Should you be buying SRNE stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Sorrento Therapeutics, including Fate Therapeutics (FATE), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Vir Biotechnology (VIR), and Twist Bioscience (TWST).

Fate Therapeutics (NASDAQ:FATE) and Sorrento Therapeutics (NASDAQ:SRNE) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, analyst recommendations, profitability, institutional ownership and risk.

Insider and Institutional Ownership

99.7% of Fate Therapeutics shares are held by institutional investors. Comparatively, 27.4% of Sorrento Therapeutics shares are held by institutional investors. 21.4% of Fate Therapeutics shares are held by company insiders. Comparatively, 3.4% of Sorrento Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Fate Therapeutics and Sorrento Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fate Therapeutics-810.13%-35.51%-25.40%
Sorrento Therapeutics-698.01%-314.06%-43.60%

Volatility and Risk

Fate Therapeutics has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 2.7, indicating that its stock price is 170% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Fate Therapeutics and Sorrento Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fate Therapeutics04902.69
Sorrento Therapeutics00403.00

Fate Therapeutics currently has a consensus target price of $108.3125, indicating a potential upside of 31.03%. Sorrento Therapeutics has a consensus target price of $28.75, indicating a potential upside of 280.79%. Given Sorrento Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sorrento Therapeutics is more favorable than Fate Therapeutics.

Earnings & Valuation

This table compares Fate Therapeutics and Sorrento Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fate Therapeutics$10.68 million725.85$-98,150,000.00($1.44)-57.40
Sorrento Therapeutics$31.43 million68.62$-292,070,000.00($2.12)-3.56

Fate Therapeutics has higher earnings, but lower revenue than Sorrento Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Fate Therapeutics beats Sorrento Therapeutics on 8 of the 14 factors compared between the two stocks.

Sorrento Therapeutics (NASDAQ:SRNE) and Acceleron Pharma (NASDAQ:XLRN) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, earnings and profitability.

Earnings and Valuation

This table compares Sorrento Therapeutics and Acceleron Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sorrento Therapeutics$31.43 million68.62$-292,070,000.00($2.12)-3.56
Acceleron Pharma$73.99 million98.60$-124,860,000.00($2.38)-50.62

Acceleron Pharma has higher revenue and earnings than Sorrento Therapeutics. Acceleron Pharma is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Sorrento Therapeutics has a beta of 2.7, suggesting that its stock price is 170% more volatile than the S&P 500. Comparatively, Acceleron Pharma has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500.

Profitability

This table compares Sorrento Therapeutics and Acceleron Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sorrento Therapeutics-698.01%-314.06%-43.60%
Acceleron Pharma-157.84%-31.62%-28.11%

Institutional and Insider Ownership

27.4% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 79.8% of Acceleron Pharma shares are owned by institutional investors. 3.4% of Sorrento Therapeutics shares are owned by insiders. Comparatively, 2.5% of Acceleron Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Sorrento Therapeutics and Acceleron Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sorrento Therapeutics00403.00
Acceleron Pharma031012.86

Sorrento Therapeutics presently has a consensus price target of $28.75, indicating a potential upside of 280.79%. Acceleron Pharma has a consensus price target of $148.2143, indicating a potential upside of 23.02%. Given Sorrento Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Sorrento Therapeutics is more favorable than Acceleron Pharma.

Summary

Acceleron Pharma beats Sorrento Therapeutics on 9 of the 15 factors compared between the two stocks.

Sorrento Therapeutics (NASDAQ:SRNE) and Halozyme Therapeutics (NASDAQ:HALO) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings.

Valuation and Earnings

This table compares Sorrento Therapeutics and Halozyme Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sorrento Therapeutics$31.43 million68.62$-292,070,000.00($2.12)-3.56
Halozyme Therapeutics$195.99 million35.39$-72,240,000.00($0.50)-96.80

Halozyme Therapeutics has higher revenue and earnings than Sorrento Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Sorrento Therapeutics has a beta of 2.7, suggesting that its share price is 170% more volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500.

Profitability

This table compares Sorrento Therapeutics and Halozyme Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sorrento Therapeutics-698.01%-314.06%-43.60%
Halozyme Therapeutics10.78%24.29%4.08%

Insider & Institutional Ownership

27.4% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 98.5% of Halozyme Therapeutics shares are held by institutional investors. 3.4% of Sorrento Therapeutics shares are held by insiders. Comparatively, 2.6% of Halozyme Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Sorrento Therapeutics and Halozyme Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sorrento Therapeutics00403.00
Halozyme Therapeutics01902.90

Sorrento Therapeutics currently has a consensus price target of $28.75, indicating a potential upside of 280.79%. Halozyme Therapeutics has a consensus price target of $42.9167, indicating a potential downside of 11.33%. Given Sorrento Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sorrento Therapeutics is more favorable than Halozyme Therapeutics.

Summary

Halozyme Therapeutics beats Sorrento Therapeutics on 9 of the 14 factors compared between the two stocks.

Sorrento Therapeutics (NASDAQ:SRNE) and Denali Therapeutics (NASDAQ:DNLI) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings.

Valuation and Earnings

This table compares Sorrento Therapeutics and Denali Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sorrento Therapeutics$31.43 million68.62$-292,070,000.00($2.12)-3.56
Denali Therapeutics$26.68 million245.69$-197,610,000.00($2.07)-26.17

Denali Therapeutics has lower revenue, but higher earnings than Sorrento Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

27.4% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 68.2% of Denali Therapeutics shares are held by institutional investors. 3.4% of Sorrento Therapeutics shares are held by insiders. Comparatively, 19.3% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Sorrento Therapeutics and Denali Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sorrento Therapeutics00403.00
Denali Therapeutics01702.88

Sorrento Therapeutics currently has a consensus price target of $28.75, indicating a potential upside of 280.79%. Denali Therapeutics has a consensus price target of $75.8571, indicating a potential upside of 40.01%. Given Sorrento Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sorrento Therapeutics is more favorable than Denali Therapeutics.

Profitability

This table compares Sorrento Therapeutics and Denali Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sorrento Therapeutics-698.01%-314.06%-43.60%
Denali Therapeutics-968.59%-39.19%-30.71%

Volatility and Risk

Sorrento Therapeutics has a beta of 2.7, suggesting that its share price is 170% more volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 2, suggesting that its share price is 100% more volatile than the S&P 500.

Summary

Denali Therapeutics beats Sorrento Therapeutics on 8 of the 14 factors compared between the two stocks.

Vir Biotechnology (NASDAQ:VIR) and Sorrento Therapeutics (NASDAQ:SRNE) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, risk, institutional ownership, earnings and analyst recommendations.

Institutional & Insider Ownership

54.5% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 27.4% of Sorrento Therapeutics shares are owned by institutional investors. 37.2% of Vir Biotechnology shares are owned by company insiders. Comparatively, 3.4% of Sorrento Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Vir Biotechnology and Sorrento Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vir Biotechnology$8.09 million747.82$-174,680,000.00($5.76)-8.21
Sorrento Therapeutics$31.43 million68.62$-292,070,000.00($2.12)-3.56

Vir Biotechnology has higher earnings, but lower revenue than Sorrento Therapeutics. Vir Biotechnology is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Vir Biotechnology has a beta of -0.99, meaning that its share price is 199% less volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 2.7, meaning that its share price is 170% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Vir Biotechnology and Sorrento Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vir Biotechnology20502.43
Sorrento Therapeutics00403.00

Vir Biotechnology currently has a consensus price target of $66.00, suggesting a potential upside of 39.62%. Sorrento Therapeutics has a consensus price target of $28.75, suggesting a potential upside of 280.79%. Given Sorrento Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sorrento Therapeutics is more favorable than Vir Biotechnology.

Profitability

This table compares Vir Biotechnology and Sorrento Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vir Biotechnology-339.61%-47.11%-39.44%
Sorrento Therapeutics-698.01%-314.06%-43.60%

Summary

Vir Biotechnology beats Sorrento Therapeutics on 8 of the 14 factors compared between the two stocks.

Sorrento Therapeutics (NASDAQ:SRNE) and Twist Bioscience (NASDAQ:TWST) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.

Valuation & Earnings

This table compares Sorrento Therapeutics and Twist Bioscience's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sorrento Therapeutics$31.43 million68.62$-292,070,000.00($2.12)-3.56
Twist Bioscience$90.10 million70.43$-139,930,000.00($3.00)-43.48

Twist Bioscience has higher revenue and earnings than Sorrento Therapeutics. Twist Bioscience is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sorrento Therapeutics and Twist Bioscience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sorrento Therapeutics-698.01%-314.06%-43.60%
Twist Bioscience-155.31%-44.62%-35.49%

Analyst Ratings

This is a summary of recent ratings and price targets for Sorrento Therapeutics and Twist Bioscience, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sorrento Therapeutics00403.00
Twist Bioscience11302.40

Sorrento Therapeutics presently has a consensus target price of $28.75, suggesting a potential upside of 280.79%. Twist Bioscience has a consensus target price of $137.50, suggesting a potential upside of 5.41%. Given Sorrento Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Sorrento Therapeutics is more favorable than Twist Bioscience.

Volatility & Risk

Sorrento Therapeutics has a beta of 2.7, meaning that its stock price is 170% more volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.

Insider and Institutional Ownership

27.4% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Twist Bioscience shares are held by institutional investors. 3.4% of Sorrento Therapeutics shares are held by insiders. Comparatively, 7.0% of Twist Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Twist Bioscience beats Sorrento Therapeutics on 8 of the 14 factors compared between the two stocks.


Sorrento Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Fate Therapeutics logo
FATE
Fate Therapeutics
1.8$82.66+5.4%$7.33 billion$10.68 million-44.92Insider Selling
Acceleron Pharma logo
XLRN
Acceleron Pharma
1.6$120.48+0.3%$7.27 billion$73.99 million-46.52
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$48.40+3.2%$6.71 billion$195.99 million302.50
Denali Therapeutics logo
DNLI
Denali Therapeutics
1.5$54.18+3.4%$6.33 billion$26.68 million-24.52
Vir Biotechnology logo
VIR
Vir Biotechnology
1.7$47.27+2.5%$6.20 billion$8.09 million-20.03Insider Selling
Twist Bioscience logo
TWST
Twist Bioscience
1.2$130.44+3.1%$6.15 billion$90.10 million-34.78Analyst Report
Kodiak Sciences logo
KOD
Kodiak Sciences
1.5$115.25+1.3%$5.82 billionN/A-49.68Analyst Report
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.6$41.66+3.3%$5.61 billion$85.07 million-43.85
China Biologic Products logo
CBPO
China Biologic Products
0.8$119.99+1.7%$4.72 billion$503.70 million33.52High Trading Volume
News Coverage
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$34.29+5.0%$4.58 billionN/A-16.10
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$73.11+2.8%$4.44 billion$20,000.00-5.20News Coverage
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$30.85+2.2%$4.43 billionN/A-16.07
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$70.47+3.7%$3.33 billionN/A-40.50Insider Selling
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$70.77+3.8%$3.04 billion$125.57 million-41.39News Coverage
Relay Therapeutics logo
RLAY
Relay Therapeutics
1.8$33.53+3.8%$2.92 billionN/A0.00Insider Selling
Revolution Medicines logo
RVMD
Revolution Medicines
1.7$40.67+5.8%$2.81 billion$50.04 million0.00News Coverage
Vericel logo
VCEL
Vericel
1.1$55.79+4.2%$2.46 billion$117.85 million-5,579,000.00Insider Selling
News Coverage
Editas Medicine logo
EDIT
Editas Medicine
1.6$35.05+1.7%$2.32 billion$20.53 million-20.14
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.5$26.20+4.0%$2.04 billionN/A-12.24Analyst Report
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.3$11.46+3.1%$1.97 billion$48.83 million-15.08
bluebird bio logo
BLUE
bluebird bio
1.8$27.33+1.9%$1.87 billion$44.67 million-2.49Analyst Report
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.3$38.26+4.1%$1.79 billionN/A0.00Analyst Report
Insider Selling
News Coverage
Gap Up
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$77.94+0.9%$1.72 billionN/A-52.66
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.55+0.2%$1.66 billion$102.43 million-19.25
Immunovant logo
IMVT
Immunovant
1.8$15.33+0.0%$1.50 billionN/A-11.88Increase in Short Interest
News Coverage
Translate Bio logo
TBIO
Translate Bio
1.6$20.11+1.6%$1.49 billion$7.80 million-18.79Gap Up
AlloVir logo
ALVR
AlloVir
1.5$22.44+0.2%$1.46 billionN/A0.00Analyst Report
Alector logo
ALEC
Alector
1.3$17.38+3.6%$1.43 billion$21.22 million-7.79Analyst Report
REGENXBIO logo
RGNX
REGENXBIO
1.6$33.06+0.7%$1.41 billion$35.23 million-13.33Increase in Short Interest
News Coverage
Replimune Group logo
REPL
Replimune Group
1.5$29.11+2.1%$1.33 billionN/A-16.45Insider Selling
News Coverage
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$30.83+1.4%$1.31 billionN/A0.00
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$25.10+0.2%$1.19 billion$100.56 million0.00Increase in Short Interest
Gap Up
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.64+2.6%$1.11 billionN/A-2.95
Mesoblast logo
MESO
Mesoblast
1.4$8.77+2.5%$1.11 billion$32.16 million-9.97Decrease in Short Interest
Scholar Rock logo
SRRK
Scholar Rock
1.5$33.05+2.9%$1.10 billion$20.49 million-13.71Increase in Short Interest
Gap Up
Cortexyme logo
CRTX
Cortexyme
1.3$37.44+0.9%$1.10 billionN/A-15.60News Coverage
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$14.55+1.9%$1.04 billion$356.07 million7.13News Coverage
Ocugen logo
OCGN
Ocugen
1.1$5.84+5.5%$1.04 billionN/A-3.95News Coverage
Gap Down
Curis logo
CRIS
Curis
1.3$9.92+1.0%$898.72 million$10 million-12.10
Vaxcyte logo
PCVX
Vaxcyte
1.7$17.77+1.7%$897.17 millionN/A0.00Increase in Short Interest
Passage Bio logo
PASG
Passage Bio
1.8$16.64+0.3%$895.48 millionN/A0.00
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$23.75+2.2%$886.06 millionN/A0.00Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.04+2.8%$879.24 millionN/A-4.14Increase in Short Interest
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.5$8.86+0.7%$873.51 million$250,000.00-6.98Gap Up
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$24.03+4.9%$871.81 millionN/A-9.93Gap Down
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$24.41+6.5%$861.71 millionN/A0.00Analyst Report
Gap Down
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$19.85+5.6%$859.56 million$42.74 million-220.56Analyst Revision
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$17.44+0.1%$818.70 million$69.89 million-4.16
Cellectis logo
CLLS
Cellectis
1.3$18.67+2.8%$780.73 million$22.99 million-9.93
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.5$4.82+2.1%$733.80 million$1.12 million-4.87Gap Up
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.